人工真皮＋塩基性線維芽細胞増殖因子 (bFGF) 併用療法から bFGF 徐放性人工真皮へ

DOI

書誌事項

タイトル別名
  • From Combination Therapy Using Artificial Dermis and Basic Fibroblast Growth Factor to Artificial Dermis for Sustained Release of bFGF

抄録

Since we developed an artificial dermis (Pelnac®, Gunze, Ltd., Kyoto, Japan), we have created improvements based on problems encountered in clinical use.<br>During the period until secondary grafting, low resistance to infection is a clinical problem. To overcome this issue, topical application of basic fibroblast growth factor (bFGF) is beneficial to induce neovascularization and accelerate the regeneration of dermis-like granulation tissues in the artificial dermis. There fore, combination therapy using artificial dermis and bFGF has been established. However, since the in vivo half-life of bFGF is very short, repeated application into the artificial dermis is required in this combination therapy. We have developed a novel artificial dermis for sustained release of bFGF. In this paper, we report the deployment circumstances and the future role of this novel matrix.

収録刊行物

  • 創傷

    創傷 4 (1), 28-35, 2013

    一般社団法人 日本創傷外科学会

キーワード

詳細情報 詳細情報について

  • CRID
    1390001205336351104
  • NII論文ID
    130004552991
  • DOI
    10.11310/jsswc.4.28
  • ISSN
    1884880X
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ